Thomas Banas, MD
Neurology · Fort Wayne, INNPI 1508863051
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,039 of the $7,615 with a category attached, or 66.2%. Avanir Pharmaceuticals, Inc. accounts for 72.0% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2019 at $7,279 and has fallen 99.5% since, to $39 in 2022.
Across 144 payments — averaging $52.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Avanir Pharmaceuticals, Inc.$5K
- UCB, Inc.$324
- AbbVie$241
- Neurocrine Biosciences, Inc.$177
- Novartis$172
- Merz North America, Inc.$132
- plus $1K from 26 others
Across 32 payments — averaging $2926.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$61K
- Biogen$14K
- Acadia Pharmaceuticals Inc$12K
- Neurocrine Biosciences, Inc.$7K
What the payments were for
- Speaking & faculty fees$5,03966%
- Travel & lodging$1222%
- Food & beverage$2,38331%
- Education$721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Avanir Pharmaceuticals, Inc. | 12 | $5,483 |
| UCB, Inc. | 33 | $324 |
| AbbVie(2 entities) | 14 | $241 |
| Neurocrine Biosciences, Inc. | 3 | $177 |
| Novartis | 9 | $172 |
| Merz North America, Inc. | 7 | $132 |
| EMD Serono, Inc. | 8 | $114 |
| AstraZeneca | 6 | $108 |
| Sanofi | 6 | $104 |
| Teva Pharmaceuticals USA, Inc. | 2 | $89 |
| Boston Scientific | 2 | $83 |
| Acadia Pharmaceuticals Inc | 9 | $78 |
| Genentech USA, Inc. | 4 | $66 |
| Aquestive Therapeutics, Inc. | 4 | $59 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| CSL Behring | 2 | $31 |
| Adamas Pharmaceuticals, Inc. | 2 | $30 |
| Biogen | 2 | $30 |
| Acorda Therapeutics, Inc | 2 | $29 |
| Amgen | 2 | $27 |
| Eisai Inc. | 2 | $25 |
| Lundbeck LLC | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Greenwich Biosciences, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Tanabe Pharma America, Inc. | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $14 |
| SK Life Science, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,615 in reported general payments places this provider in the 70th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 19 | $546 |
| Gabapentin | 13 | $310 |
| Lamotrigine | 14 | $287 |
| Primidone | 17 | $233 |
| Donepezil Hcl | 17 | $130 |
| Zonisamide | 13 | $126 |
Paid to pharmacies, not to this prescriber.
Other neurology in Fort Wayne
- Ajay GuptaFort Wayne$411K
- Marlene BultemeyerFort Wayne$277K
- Andrea HallerFort Wayne$242K
- Paul LaterFort Wayne$132K
- Christopher VachonFort Wayne$27K
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.